drugset / Trial / NCT05265234

Dupilmuab for Atopic Dermatitis Monitored With Noninvasive Imaging.

NCT05265234

NaSingle-groupOpen-labelTreatment

Summary

The study is trying to answer the following question: "Can we use non-invasive imaging to evaluate the response of atopic dermatitis (eczema) to Dupixent (dupilumab)?"

Timeline

Start
2022-03-01
Primary completion
2023-03-01
Completion
2024-03-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Dupilumab Monoclonal antibody 300 mg Subcutaneous

Indications